某三甲医院近5年核苷类抗乙肝病毒用药状况

Application of nucleotide drugs against hepatitis B virus in a grade-Ⅲ class-A hospital in recent 5 years

目的：为了合理应用核苷类抗乙肝病毒药物,在2015年各指南发布之际分析比对某代表性三甲医院近五年该类药物临床用药状况。方法：收集2010至2014年该院核苷类抗乙肝病毒药使用的金额和数量,用限定日剂量排序法分析。结果：五年中核苷类抗乙肝病毒药的年销售金额在334.66万-812.70万元,其中恩替卡韦呈逐年增长趋势,在2013年跃居首位,而拉米夫定呈下降趋势。结论：该院口服核苷类抗乙肝病毒药的应用基本符合相关指南,应优化诊疗对策尤其是在育龄时期。

OBJECTIVE To rationally use nucleotide drugs against hepatitis B virus（HBV）,its clinical application was analyzed in a grade-Ⅲclass-A hospital in recent 5 years when some new guidelines were issued.METHODS Consumption quantity and sum of nucleotide drugs against HBV were analyzed from2010 to 2014 by using method of defined daily dose.RESULTSAnnual consumption sum of nucleotide drugs against HBV was up to 3 346.6 thousand-8 127 thousand yuan in5 years.Entecavir showed an increasing trend and ranked the first in2013,but lamivudine showed a declining trend.CONCLUSION Application of nucleotide drugs against HBV in this hospital is basically accordant with relevant guidelines.Countermeasures should be optimized for diagnosis and therapy,especially for women during childbearing age.